Teva Raises 2026 Revenue Guidance to $16.7-$17B
The Israeli drugmaker lifted its full-year outlook after third-quarter revenue beat analyst expectations, led by branded products.
Updated on Nov. 3, 2026 in Corporate Finance
Teva reported third-quarter 2026 revenue of $4.4 billion, above analyst predictions of $4.2 billion, and raised its annual revenue guidance to $16.7-$17 billion. Non-GAAP earnings per share came in at $0.86, versus a consensus of $0.72.
Why it matters
The raised outlook reflects growth in Teva's innovative branded medicines, which are increasingly offsetting pressure on its older product lines. For investors tracking global generic and specialty drugmakers, the results signal how the company's shift toward branded products is affecting its earnings profile.
Teva's three key innovative brands grew 33% in local currency to approximately $1.1 billion year-over-year, while GAAP net profit fell 46% to $233 million against non-GAAP net profit of $1 billion. Teva's debt stood at $16.7 billion at the end of the third quarter.
The players
Teva Pharmaceutical Industries
Teva is a global pharmaceutical company headquartered in Israel, known for generic medicines and a growing portfolio of branded specialty drugs.
The details
Teva raised its annual revenue guidance in August when it released second-quarter results, then raised it again alongside third-quarter results on November 3, 2026. The increase was driven by branded products including Austedo, Ajovy, and Uzedy, which the company cited alongside margin expansion and cash flow generation.
Timeline
August 2026: Teva released second-quarter results and raised revenue guidance to $16.5-$16.85 billion.
November 3, 2026: Teva announced raised guidance alongside third-quarter financial results.
Market Dynamics
The raised outlook extends Teva's ongoing move from low-margin generics toward branded specialty drugs, a shift that has reshaped the company's revenue mix over several years. Branded growth is now lifting full-year guidance even as the company's total revenue declined about 2% year-over-year in the third quarter.
For investors holding Teva shares, the raised guidance and the gap between GAAP and non-GAAP profit are the two numbers to weigh when assessing near-term earnings quality. The company's $16.7 billion in debt is a relevant factor for anyone modeling its cash flow and capacity for future shareholder returns.
The takeaway
Investors evaluating Teva should look beyond the headline revenue beat, since GAAP net profit fell 46% while non-GAAP profit rose 11.3%. Tracking how quickly branded products like Austedo and Ajovy grow will show whether the guidance raise is sustainable.
Further reading
For more on how drugmakers report and guide their earnings, see Corporate Finance.
